News and Press Releases
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved responses and long-term...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 13, 2025
Pharmapack Predictions 2025: the Good the Bad and…. the Donald 2.0
Biologic approvals, drug delivery advancements, GLP-1 generics and the long-sought funding return to drive a record year in 2025 7 January 2025 – Paris, France – Pharmapack Europe & CPHI...
Category: Biotechnology, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: January 13, 2025
Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
Switzerland’s Basel Region Crowned ‘Europe’s Top Destination to Launch a Drug Device Company’, According to Pharmapack Report
Pharmapack Europe: ‘Basel the best location for drug device innovation in Europe thanks to combination of world class manufacturing and existing biomedical research infrastructure’ 18 December 2024 – Paris, France...
Category: Drug Delivery, Drug Discovery
Posted: January 13, 2025
Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
Paris voted the ‘heart of pharma’ in Europe
Pharmapack Europe research reveals Île-de-France is the second-best location in Europe for ‘drug manufacturing’ and to ‘start a biotech’ Paris, France – The global drug delivery and packaging industry arrives...
Category:
Posted: January 13, 2025
Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
Abu Dhabi to Host Inaugural Pharma Logistics Winter University
The inaugural Pharma Logistics Winter University, co-founded by the Department of Health – Abu Dhabi, Etihad Cargo, Pharma.Aero, the University of Antwerp, and Khalifa University of Science and Technology, offers...
Category: Logistics, Pharmaceutical
Posted: January 13, 2025
Gilead and Leo Pharma Enter into Strategic Partnership to Accelerate Development of Oral STAT6 Program with Potential in Multiple Inflammatory Diseases
Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders Gilead Will Have Exclusive Global Rights to the STAT6...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 11, 2025
Phillips Medisize Expands Its Inhalation Drug Delivery Capabilities
Molex, a parent to Phillips Medisize, Closes Acquisition of Vectura Group Ltd. Phillips Medisize adds market-leading inhalation capabilities to its existing suite of drug delivery device design and production capabilities. ...
Category: Drug Delivery, Manufacturing and Packing
Posted: January 10, 2025
Biofidelity and CellCarta partner to deploy Aspyre® Lung in global clinical trials
9 January 2025 – Cambridge, United Kingdom and Montreal, Canada – Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for...
Category:
Posted: January 9, 2025
Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials
9 January 2025 -- Cambridge, UK and Montreal, Canada -- Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmaceutical...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 9, 2025
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV IRAKLIA is...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 9, 2025
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 9, 2025
DeanHouston Appoints New Director of Hygienic Markets
Jeff Blease brings more than 31 years of industry experience 8 January 2025 -- Kentucky, US -- DeanHouston, a business-first marketing firm that excels at creating meaningful communication strategies for...
Category: Other
Posted: January 8, 2025
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients
8 January 2025 -- Basel, Switzerland -- Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration....
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 8, 2025
Mittlere Strasse 91, CH-4031 Basel, Switzerland
QurAlis Invited to Present at 43rd Annual J.P. Morgan Healthcare Conference
7 January 2025 -- Massaschusetts, US -- QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of amyotrophic...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 7, 2025
Evaluate Releases 2025 Preview for Pharma Market
7 January 2025 – London, UK – Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 Preview report featuring updated forecasts for the biopharma...
Category:
Posted: January 7, 2025
